NEW YORK, Feb. 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Why Did TransMedics’s Stock Drop? TransMedics is a medical technology company that develops systems to preserve and asses ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Why Did TransMedics’s Stock Drop? TransMedics is a medical technology company that develops systems to preserve and asses ...

NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into TransMedics Group, Inc. (NASDAQ: TMDX) for potential violations of the federal securities laws. If you invested in TransMedics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/transmedics-group-inc. Why Did TransMedics’s Stock Drop? TransMedics is a medical technology company that develops systems to preserve and asses ...

LOS ANGELES, Jan. 28, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ: TMDX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. TransMedics is the subject of a report issued by Scorpion Capital on J ...

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDAQ: TMDX) resulting from allegations that TransMedics may have issued materially misleading business information to the investing public.So What: If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee a ...

Stock Performance - TransMedics Group Inc (TMDX) stock has plunged 49 2% in the past three months underperforming the industry's 6 8% rise and the S&P 500's 5 7% growth [1] - Over the past three months TMDX's stock performance has been bleak compared to peers like Medtronic plc (MDT) GE HealthCare Technologies Inc (GEHC) and Abbott Laboratories (ABT) with MDT and GEHC shares plunging 3 5% and 1 8% respectively while ABT's shares gained 1 1% [7] Financial Results and Outlook - TransMedics announced its third-quarter 2024 results with total revenues declining 5% sequentially driven by a 3% sequential drop in U S revenues and a 45% sequential drop in international revenues (OUS) [3] - The company narrowed its 2024 financial outlook expecting revenues for the full year to be in the range of $428 million-$432 million representing growth of 77-79% from the comparable 2023 period compared to the prior outlook of $425 million to $445 million [4] - The Zacks Consensus Estimate for 2024 revenues is currently pegged at $430 3 million indicating a 78 1% improvement from the comparable 2023 period [4] Operational Challenges - TransMedics' OUS revenues declined 40% year over year and 45% sequentially in the third quarter of 2024 due to the lumpiness of international orders and the lack of broad national reimbursement outside of the United States [8] - The company faces rising costs of fuel parts and maintenance due to inflation directly impacting its growing logistics and aviation infrastructure Additionally inflation-induced wage increases could have raised costs for hiring and training pilots and other staff for the National OCS Program (NOP) [12] Macroeconomic Impacts - The Federal Reserve's aggressive interest rate hikes have increased the cost of capital for TransMedics raising the cost of financing and pressuring profitability Higher interest rates also reduce the present value of future cash flows particularly for growth-oriented companies like TransMedics [9] - In the current macroeconomic climate characterized by high-interest rates and economic uncertainty growth-oriented stocks like TransMedics face valuation compressions as investors prioritize profitability over growth [10] - A strong dollar makes U S -based exports more expensive for international customers which could partly explain the sharp decline in OUS revenues [11] Product Development and Reimbursement - TransMedics has a long history and broad experience in the development of warm machine perfusion for organ preservation and continues to add technological and usability enhancements to its OCS technology platform [15] - The OCS has been reimbursed by the Centers for Medicare & Medicaid Services and private insurers during TransMedics' clinical trials and continues to be reimbursed in the commercial setting [16] Stock Valuation and Estimates - TransMedics' forward 12-month P/S of 3 9X is lower than the industry's average of 4 7X and its five-year median of 9 9X [17] - Estimates for TransMedics' 2024 earnings have remained flat at $1 00 in the past 60 days [18] Activist Short-Selling Allegations - Activist short-selling firm Scorpion Capital alleged that TransMedics was involved in kickbacks billing fraud and unreported device failures The report also accused the company of steering damaged or rejected organs to select transplant centers engaging in off-label use of its OCS and overcharging hospitals through its NOP [13]

PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Ltd. (NASDAQ: TMDX) (“TransMedics” or the “Company”). The investigation concerns whether TransMedics and certain of its officers and/or directors have engaged in securities fraud. PLEASE CLICK HERE TO PROV ...

Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities Investigation ...

Core Viewpoint - TransMedics Group, Inc. (TMDX) has issued a statement refuting allegations made by short-seller Scorpion Capital, asserting that the claims are inaccurate and misleading, while reaffirming its commitment to operational integrity and compliance [1][8]. Company Performance - Following the announcement, TMDX shares dropped by 10.8%, closing at $57.2, and have seen a significant decline of 54% over the past three months, contrasting with the industry's growth of 1.2% and the S&P 500's increase of 3.4% during the same period [2]. - TMDX currently has a market capitalization of $1.92 billion and missed earnings estimates by 57.14% in the last reported quarter [4]. Allegations and Response - Scorpion Capital's report accused TransMedics of unethical practices, including kickbacks, billing fraud, and unreported device failures, suggesting these actions could lead to a customer exodus and financial decline, with a target stock price of $0 [5][7]. - In response, TransMedics categorically denied the allegations, stating they were baseless and aimed at market manipulation, while emphasizing its commitment to compliance and improving clinical outcomes in organ transplantation [8][9]. Future Outlook - The controversy surrounding the allegations could potentially benefit TMDX's share price in the long run if managed effectively, as the company's strong rebuttal may reassure investors and strengthen their confidence [3]. - TransMedics is preparing for significant business developments, including the launch of next-generation OCS Heart and OCS Lung programs in 2025 [9].

TMDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into TransMedics Group, Inc. and Encourages Investors to Contact the Firm ...